In MS, atacicept, a BAFF antagonist, has been proposed to be a promising treatment strategy based on animal models of MS, but caused unexpected increased inflammatory activity in MS patients, which might be related to a loss of interleukin-10-producting plasma cells [202,203,204,205]. Here, IL10 is linked to myeloid sarcoma.